Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed)

Background
The National Institutes of Health (NIH), specifically the National Institute of Neurological Disorders and Stroke (NINDS), is issuing this funding opportunity to support exploratory and developmental research aimed at understanding, preventing, or treating Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

The goal is to accelerate research that leads to improved understanding and treatments for these rare autoimmune neuropathies, which cause damage to peripheral nerves.

Grant Details
The grant will support studies focused on:
1) Immunological mechanisms of nerve damage/dysfunction;
2) Contributing genetic/epigenetic factors;
3) Novel animal/cellular model systems;
4) Discovery of novel diagnostic or treatment response biomarkers;
5) Development of novel treatments or mechanisms of action of existing treatments.

Applications must propose innovative studies that address these areas and may not include clinical trials.

Eligibility Requirements
Eligible applicants include higher education institutions, public/state controlled institutions, private institutions, nonprofits, for-profit organizations, small businesses, local governments, state governments, tribal governments, federal agencies, and foreign organizations. Individuals from diverse backgrounds are encouraged to apply.

Period of Performance
The total project period may not exceed two years. The anticipated start date for successful applications is March 3, 2025.

Grant Value
NIH intends to commit an estimated total of $3,000,000 to fund approximately 7 awards. The combined budget for direct costs may not exceed $275,000 over the two-year project period, with no more than $200,000 requested in any single year.